Welcome to our dedicated page for Corcept Therapeutics news (Ticker: CORT), a resource for investors and traders seeking the latest updates and insights on Corcept Therapeutics stock.
Corcept Therapeutics Incorporated (NASDAQ: CORT) is a leader in developing cortisol-modulating therapies for metabolic, oncologic, and neuropsychiatric disorders. This page serves as the definitive source for verified news and regulatory updates about the company.
Access real-time press releases, clinical trial developments, and financial disclosures essential for tracking CORT's progress in pharmaceutical innovation. Our curated collection includes updates on GR antagonist research, FDA communications, and partnership announcements.
Key content categories include quarterly earnings reports, drug approval milestones, scientific conference presentations, and strategic collaborations. Investors will find timely information about Korlym® commercialization and pipeline advancements across 300+ proprietary compounds.
Bookmark this page for direct access to Corcept's official communications. Check regularly for updates on hypercortisolism treatments, oncology trials, and novel therapeutic applications of glucocorticoid receptor science.
Corcept Therapeutics (NASDAQ: CORT) has announced the completion of enrollment for its GRATITUDE trial, investigating miricorilant as a treatment for weight gain induced by antipsychotics in patients with schizophrenia or bipolar disorder. The trial, which includes 600 mg of miricorilant or placebo daily over 12 weeks, aims to evaluate weight reduction and safety. Data is expected in Q4 2022. Additionally, the company is conducting a second trial, GRATITUDE II, for long-term antipsychotic-induced weight gain, with results also due in Q4. Both studies are vital for addressing metabolic side effects of antipsychotics.
Corcept Therapeutics (CORT) announced promising Phase 2 trial results for relacorilant combined with nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer. The treatment showed a 33% overall reduction in risk of death compared to nab-paclitaxel alone (hazard ratio: 0.67; p-value: 0.066). When excluding patients with severe prior therapies, the benefit increased to 48% (hazard ratio: 0.52; p-value: 0.010). The company plans to initiate a Phase 3 trial in Q2 2022 and aims to establish relacorilant as a new standard of care for this difficult-to-treat population.
Corcept Therapeutics (NASDAQ: CORT) has scheduled an investor event on March 31, 2022, to discuss its ovarian cancer program, including results from a Phase 2 study of relacorilant combined with nab-paclitaxel for patients with advanced, platinum-resistant ovarian cancer.
The study involved 178 patients and showed improved progression-free survival, particularly in the intermittent dosing group, which had a median PFS of 5.6 months versus 3.8 months for nab-paclitaxel alone. The company plans to initiate a Phase 3 trial in Q2 2022.
Corcept Therapeutics reported strong financial results for Q4 2021, with revenue of $98.8 million, up from $85.7 million in Q4 2020. Total revenue for 2021 reached $366.0 million, compared to $353.9 million in 2020. The company announced a positive revenue guidance for 2022 of $400 - $430 million. Q4 GAAP net income was $32.1 million, an increase from $26.0 million year-over-year. Corcept plans to launch a Phase 2 trial for ALS and has ongoing trials for ovarian cancer and NASH, projecting significant data releases throughout 2022.
Corcept Therapeutics (CORT) will report its fourth quarter and full-year 2021 financial results on February 15, 2022, followed by a corporate update. A conference call will be held that day at 5:00 p.m. ET.
The company has developed proprietary compounds to modulate cortisol effects and is conducting clinical trials for several serious disorders, including Cushing’s syndrome, ovarian cancer, and more. Korlym®, its FDA-approved medication for Cushing’s syndrome, highlights its market presence.
Corcept Therapeutics (NASDAQ: CORT) announced the final results of its tender offer to purchase up to 10,000,000 shares of common stock, which expired on December 15, 2021. A total of 31,661,302 shares were tendered. Corcept has accepted for purchase 10,000,000 shares at $20.75 each, totaling $207.5 million. This acquisition represents approximately 9% of the total shares outstanding. Due to high participation, about 35% of the properly tendered shares were accepted on a pro-rata basis. Unaccepted shares will be returned to stockholders promptly.
Corcept Therapeutics (NASDAQ: CORT) announced preliminary results for its tender offer to buy up to 10 million shares of common stock, which ended on December 15, 2021. A total of 31,743,651 shares were validly tendered at or below the maximum purchase price of $23.75. Corcept plans to purchase approximately 10 million shares at $20.75 each, totaling around $207.5 million. Due to oversubscription, only about 35% of the tendered shares will be accepted. Following the buyback, approximately 105,933,592 shares will remain outstanding.
Corcept Therapeutics (NASDAQ: CORT) announced a Tender Offer to purchase up to 10,000,000 shares of its common stock, with a price ranging between $20.75 and $23.75 per share, closing on December 15, 2021. The Board of Directors deemed it advisable to proceed with the offer, despite stock price fluctuations, and opted not to terminate the offer. The Tender Offer's terms remain unchanged except for the waived price condition. No recommendations were made regarding shareholder participation.
Corcept Therapeutics (NASDAQ: CORT) has announced an extension of its tender offer for shares of common stock, moving the expiration from December 7, 2021, to December 15, 2021. A total of 8,282,336 shares have been tendered so far, with the offer contingent on at least three million shares being accepted. Stockholders who have already tendered their shares do not need to take further action. The terms of the tender offer remain unchanged, and the company has not made recommendations regarding participation.
Corcept Therapeutics (NASDAQ: CORT) will present at two upcoming investor conferences. The Jefferies London Healthcare Conference is on November 16, 2021, at 5:00 pm GMT, featuring a fireside chat format. The Evercore ISI 4th Annual HealthCONx Conference is scheduled for November 30, 2021, at 11:20 am EST, also in a fireside chat format.
Corcept specializes in developing drugs for serious metabolic, oncologic, and neuropsychiatric disorders by modulating cortisol. Its product Korlym® is FDA-approved for Cushing’s syndrome, supported by a robust portfolio of proprietary cortisol modulators.
